<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="143109">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02149784</url>
  </required_header>
  <id_info>
    <org_study_id>20140413</org_study_id>
    <nct_id>NCT02149784</nct_id>
  </id_info>
  <brief_title>Effectiveness Study of Resection of Primary Tumor in Stage IV Colorectal Cancer Patients</brief_title>
  <official_title>Palliative Resection of Asymptomatic Primary Tumor Following Effective Induction Chemotherapy in Colorectal Cancer Patients With Unresectable Distant Metastasis: a Multi-center, Prospective, Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <authority>China: Sun Yat-Sen University Cancer Center Ethic Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is still no perfect treatment suggestion for patients with asymptomatic colorectal
      cancer with unresectable metastatic disease. Whether patients can benefit from palliative
      resection of primary tumor or not is still waiting for answer. The investigators hypothesis
      that asymptomatic metastatic colorectal cancer patients who respond to chemotherapy will
      benefit from primary tumor resection.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events both in surgery group and chemotherapy group</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Surgical treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Unresectable mCRC patients who respond to chemotherapy will receive surgical resection of primary tumor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Unresectable mCRC patients who were respond to chemotherapy will continue with chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical resection of primary tumor</intervention_name>
    <description>Surgical resection of primary tumor of mCRC patients who were respond to first line chemotherapy`</description>
    <arm_group_label>Surgical treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 70 years old

          -  both genders

          -  ECOG:0-2 score

          -  Pathological confirmed colon cancer or rectal cancer with at least 12 cm far away
             from anal verge

          -  CT,MRI,or PET-CT confirmed  metastasis

          -  MDT confirmed unresectable metastasis lesion

          -  No evidence of obstruction, bleeding, perforation

          -  WBC≥4.0×109/L，Neu ≥2.0×109/L，PLT≥100×109/L

          -  No contraindication for chemotherapy

          -  No evidence of other malignant tumor

          -  Expected survival time &gt; 6 months

        Exclusion Criteria:

          -  mCRC patients who did not respond to first line chemotherapy

          -  Require surgical intervention during the primary tumor-related symptoms

          -  Obvious coagulopathy

          -  Severe heart, liver, kidney damage or other serious uncontrolled medical illness or
             acute infection, cachexia

          -  Severe organ damage after chemotherapy, surgery or unable to continue to systemic
             chemotherapy

          -  Pregnant or lactating women or women of childbearing age who refuse to accept
             contraception.

          -  Nearly three months participated in clinical trials of other persons.

          -  Mental abnormalities
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gong Chen, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhi-zhong Pan, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>De-Sen Wan, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gong Chen, Prof.</last_name>
    <phone>+86 20 87343584</phone>
    <email>Chengong@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gong Chen, Prof.</last_name>
      <phone>+86 20 87343584</phone>
      <email>chengong@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Gong Chen, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rong-Xin Zhang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu-Hong Li, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ling-Hneg Kong, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhi-qiang Wang, PhD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiao-Jun Wu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhi-Zhong Pan, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yan-Hong Deng, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hui Wang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meng Qiu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 25, 2014</lastchanged_date>
  <firstreceived_date>May 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Gong Chen</investigator_full_name>
    <investigator_title>Sun Yat-Sen University Cancer Center</investigator_title>
  </responsible_party>
  <keyword>Metastasis colorectal cancer</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Resection of primary tumor</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
